IL282359B2 - שיטות להכנה של ריליזאט מתסיות - Google Patents
שיטות להכנה של ריליזאט מתסיותInfo
- Publication number
- IL282359B2 IL282359B2 IL282359A IL28235921A IL282359B2 IL 282359 B2 IL282359 B2 IL 282359B2 IL 282359 A IL282359 A IL 282359A IL 28235921 A IL28235921 A IL 28235921A IL 282359 B2 IL282359 B2 IL 282359B2
- Authority
- IL
- Israel
- Prior art keywords
- platelet
- containing space
- releasate
- calcium
- lysate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 123
- 239000000203 mixture Substances 0.000 claims description 149
- 239000006166 lysate Substances 0.000 claims description 125
- 239000011521 glass Substances 0.000 claims description 122
- 239000003634 thrombocyte concentrate Substances 0.000 claims description 111
- 239000002245 particle Substances 0.000 claims description 107
- 210000004369 blood Anatomy 0.000 claims description 97
- 239000008280 blood Substances 0.000 claims description 97
- 159000000007 calcium salts Chemical class 0.000 claims description 88
- 239000001963 growth medium Substances 0.000 claims description 60
- 229910001424 calcium ion Inorganic materials 0.000 claims description 48
- 210000001519 tissue Anatomy 0.000 claims description 25
- -1 Ca2+ ions Chemical class 0.000 claims description 24
- 239000005361 soda-lime glass Substances 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 208000002193 Pain Diseases 0.000 claims description 14
- 201000008482 osteoarthritis Diseases 0.000 claims description 14
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 13
- 206010061246 Intervertebral disc degeneration Diseases 0.000 claims description 13
- 208000026137 Soft tissue injury Diseases 0.000 claims description 12
- 239000001110 calcium chloride Substances 0.000 claims description 12
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 12
- 235000011148 calcium chloride Nutrition 0.000 claims description 12
- 210000004209 hair Anatomy 0.000 claims description 12
- 206010003694 Atrophy Diseases 0.000 claims description 11
- 208000020084 Bone disease Diseases 0.000 claims description 11
- 208000023715 Ocular surface disease Diseases 0.000 claims description 11
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 11
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 11
- 208000016599 Uterine disease Diseases 0.000 claims description 11
- 230000037444 atrophy Effects 0.000 claims description 11
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 11
- 239000002537 cosmetic Substances 0.000 claims description 11
- 208000011099 endometrial disease Diseases 0.000 claims description 11
- 208000027866 inflammatory disease Diseases 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 11
- 208000004631 alopecia areata Diseases 0.000 claims description 10
- 229960002713 calcium chloride Drugs 0.000 claims description 10
- 230000002934 lysing effect Effects 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000005388 borosilicate glass Substances 0.000 claims description 5
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 claims description 4
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 4
- 239000001639 calcium acetate Substances 0.000 claims description 4
- 229960005147 calcium acetate Drugs 0.000 claims description 4
- 235000011092 calcium acetate Nutrition 0.000 claims description 4
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 4
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 229960003563 calcium carbonate Drugs 0.000 claims description 4
- YALMXYPQBUJUME-UHFFFAOYSA-L calcium chlorate Chemical compound [Ca+2].[O-]Cl(=O)=O.[O-]Cl(=O)=O YALMXYPQBUJUME-UHFFFAOYSA-L 0.000 claims description 4
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 4
- 229960002283 calcium glubionate Drugs 0.000 claims description 4
- YPCRNBPOUVJVMU-LCGAVOCYSA-L calcium glubionate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YPCRNBPOUVJVMU-LCGAVOCYSA-L 0.000 claims description 4
- 229940078512 calcium gluceptate Drugs 0.000 claims description 4
- 239000000920 calcium hydroxide Substances 0.000 claims description 4
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 4
- 229940095643 calcium hydroxide Drugs 0.000 claims description 4
- 235000011116 calcium hydroxide Nutrition 0.000 claims description 4
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 4
- 239000001527 calcium lactate Substances 0.000 claims description 4
- 235000011086 calcium lactate Nutrition 0.000 claims description 4
- 229960002401 calcium lactate Drugs 0.000 claims description 4
- FATUQANACHZLRT-XBQZYUPDSA-L calcium;(2r,3r,4s,5r,6r)-2,3,4,5,6,7-hexahydroxyheptanoate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O FATUQANACHZLRT-XBQZYUPDSA-L 0.000 claims description 4
- RAFRTSDUWORDLA-UHFFFAOYSA-N phenyl 3-chloropropanoate Chemical compound ClCCC(=O)OC1=CC=CC=C1 RAFRTSDUWORDLA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000005354 aluminosilicate glass Substances 0.000 claims description 3
- 239000004227 calcium gluconate Substances 0.000 claims description 3
- 235000013927 calcium gluconate Nutrition 0.000 claims description 3
- 229960004494 calcium gluconate Drugs 0.000 claims description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 3
- 239000005350 fused silica glass Substances 0.000 claims description 3
- 239000005355 lead glass Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 210000001772 blood platelet Anatomy 0.000 description 452
- 239000000523 sample Substances 0.000 description 68
- 239000011324 bead Substances 0.000 description 58
- 239000012530 fluid Substances 0.000 description 57
- 238000004891 communication Methods 0.000 description 51
- 239000000243 solution Substances 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 43
- 230000015271 coagulation Effects 0.000 description 36
- 238000005345 coagulation Methods 0.000 description 36
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 35
- 239000000654 additive Substances 0.000 description 34
- 230000000996 additive effect Effects 0.000 description 32
- 210000003491 skin Anatomy 0.000 description 27
- 238000001556 precipitation Methods 0.000 description 25
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 21
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 20
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 19
- 239000011575 calcium Substances 0.000 description 19
- 229960005069 calcium Drugs 0.000 description 19
- 229910052791 calcium Inorganic materials 0.000 description 19
- 239000012091 fetal bovine serum Substances 0.000 description 19
- 210000002381 plasma Anatomy 0.000 description 18
- 239000011148 porous material Substances 0.000 description 16
- 238000001914 filtration Methods 0.000 description 15
- 239000003102 growth factor Substances 0.000 description 15
- 238000012546 transfer Methods 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 12
- 210000000130 stem cell Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000003466 welding Methods 0.000 description 12
- 230000010261 cell growth Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 108090000190 Thrombin Proteins 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 10
- 244000052769 pathogen Species 0.000 description 10
- 238000010257 thawing Methods 0.000 description 10
- 229960004072 thrombin Drugs 0.000 description 10
- 229910019142 PO4 Inorganic materials 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000010452 phosphate Substances 0.000 description 9
- 210000004623 platelet-rich plasma Anatomy 0.000 description 9
- 210000001778 pluripotent stem cell Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000012190 activator Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000007710 freezing Methods 0.000 description 7
- 230000008014 freezing Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000010118 platelet activation Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 5
- 206010013774 Dry eye Diseases 0.000 description 5
- 108010074860 Factor Xa Proteins 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 108010000499 Thromboplastin Proteins 0.000 description 5
- 102000002262 Thromboplastin Human genes 0.000 description 5
- 238000002617 apheresis Methods 0.000 description 5
- 239000003114 blood coagulation factor Substances 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 208000008035 Back Pain Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 208000008930 Low Back Pain Diseases 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 102000013275 Somatomedins Human genes 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 238000002834 transmittance Methods 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
- 206010031264 Osteonecrosis Diseases 0.000 description 3
- 208000010332 Plantar Fasciitis Diseases 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 208000000491 Tendinopathy Diseases 0.000 description 3
- 206010047642 Vitiligo Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 208000018180 degenerative disc disease Diseases 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000012606 in vitro cell culture Methods 0.000 description 3
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 3
- 230000006623 intrinsic pathway Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229960003330 pentetic acid Drugs 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102000009840 Angiopoietins Human genes 0.000 description 2
- 108010009906 Angiopoietins Proteins 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010006811 Bursitis Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 102100023804 Coagulation factor VII Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 108010080865 Factor XII Proteins 0.000 description 2
- 102000000429 Factor XII Human genes 0.000 description 2
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 2
- 208000005230 Leg Ulcer Diseases 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108090000778 Platelet factor 4 Proteins 0.000 description 2
- 102000004211 Platelet factor 4 Human genes 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010059604 Radicular pain Diseases 0.000 description 2
- 208000024288 Rotator Cuff injury Diseases 0.000 description 2
- 206010039227 Rotator cuff syndrome Diseases 0.000 description 2
- 208000007613 Shoulder Pain Diseases 0.000 description 2
- 206010043255 Tendonitis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000011882 arthroplasty Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940064551 bovine heparin Drugs 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000011124 ex vivo culture Methods 0.000 description 2
- 230000028023 exocytosis Effects 0.000 description 2
- 230000006624 extrinsic pathway Effects 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 229940012413 factor vii Drugs 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000004868 gas analysis Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000012285 hip pain Diseases 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 239000011236 particulate material Substances 0.000 description 2
- 229920009441 perflouroethylene propylene Polymers 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 229940045627 porcine heparin Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000031019 skin pigmentation disease Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000004415 tendinitis Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- QBYMCVQZZZQPHE-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;calcium Chemical compound [Ca].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O QBYMCVQZZZQPHE-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001451794 Cerus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- 241000247627 Elusimicrobia bacterium Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 201000011275 Epicondylitis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 230000026769 Factor XII activation Effects 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101800001015 Glycocalicin Proteins 0.000 description 1
- 102400000446 Glycocalicin Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 108010085662 ecarin Proteins 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000002459 porosimetry Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000003259 prostaglandin group Chemical group 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000010832 regulated medical waste Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000018448 secretion by cell Effects 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Substances [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000002821 viper venom Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000000207 volumetry Methods 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/983—Blood, e.g. plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Lubricants (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18206107 | 2018-11-14 | ||
| PCT/EP2019/081257 WO2020099530A1 (en) | 2018-11-14 | 2019-11-14 | Methods for preparing platelet releasate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL282359A IL282359A (he) | 2021-05-31 |
| IL282359B1 IL282359B1 (he) | 2023-10-01 |
| IL282359B2 true IL282359B2 (he) | 2024-02-01 |
Family
ID=64316317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL282359A IL282359B2 (he) | 2018-11-14 | 2019-11-14 | שיטות להכנה של ריליזאט מתסיות |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220008475A1 (he) |
| EP (1) | EP3880217B1 (he) |
| JP (1) | JP7416786B2 (he) |
| KR (1) | KR20210091760A (he) |
| CN (1) | CN113164522B (he) |
| AU (1) | AU2019380640A1 (he) |
| CA (1) | CA3113888A1 (he) |
| ES (1) | ES2970156T3 (he) |
| IL (1) | IL282359B2 (he) |
| PL (1) | PL3880217T3 (he) |
| WO (1) | WO2020099530A1 (he) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200015440A (ko) * | 2016-11-18 | 2020-02-12 | 파워 오브 플레이틀렛츠 피티이. 엘티디. | 혈소판 분비물질을 함유하는 성장 인자들을 마련하는 방법 |
| EP4276173A1 (en) * | 2022-05-10 | 2023-11-15 | Stemmatters, Biotecnologia e Medicina Regenerativa, S.A. | Stable human platelet lysate composition, methods and uses thereof |
| CN115125191B (zh) * | 2022-08-22 | 2023-10-13 | 浙江绿蔻生物技术有限公司 | 成纤维细胞转化培养基及其应用、成纤维细胞的制备方法 |
| WO2024159177A1 (en) * | 2023-01-26 | 2024-08-02 | Regenexx Llc | Use of platelet lysate to return macrophage cells to their resting state |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4340049A (en) | 1979-10-18 | 1982-07-20 | Baxter Travenol Laboratories, Inc. | Breakaway valve |
| JPS6420858A (en) | 1987-07-16 | 1989-01-24 | Terumo Corp | Tube body equipped with plug body separable by breakage |
| JP4110285B2 (ja) * | 2003-03-07 | 2008-07-02 | 愛知県 | 血清の製造方法 |
| JP4752504B2 (ja) * | 2003-05-21 | 2011-08-17 | 株式会社ジェイ・エム・エス | 血液成分分離収容装置 |
| WO2005065242A2 (en) * | 2003-12-29 | 2005-07-21 | Am Biosolutions | Method of treating cancer using platelet releasate |
| US7694828B2 (en) * | 2005-04-27 | 2010-04-13 | Biomet Manufacturing Corp. | Method and apparatus for producing autologous clotting components |
| GB201004072D0 (en) * | 2010-03-11 | 2010-04-28 | Turzi Antoine | Process, tube and device for the preparation of wound healant composition |
| US20120230967A1 (en) * | 2011-03-08 | 2012-09-13 | Howmedica Osteonics Corp. | Device and method to activate platelets |
| US9011846B2 (en) * | 2011-05-02 | 2015-04-21 | Biomet Biologics, Llc | Thrombin isolated from blood and blood fractions |
| AU2012275562B2 (en) * | 2011-06-27 | 2016-10-20 | Children's Healthcare Of Atlanta, Inc. | Compositions, uses, and preparation of platelet lysates |
| CN104508124B (zh) * | 2011-07-06 | 2017-11-17 | 细胞治疗有限公司 | 中胚层谱系祖细胞 |
| JP6452271B2 (ja) * | 2012-12-13 | 2019-01-16 | 株式会社ジェイ・エム・エス | 血清の調製方法 |
| EP2948210A4 (en) * | 2013-01-28 | 2016-10-19 | Regenerative Sciences Llc | DEVICE AND METHODS FOR LYING OR ACTIVATION OF BLOOD PLAQUETTES |
| GB201411913D0 (en) * | 2014-07-03 | 2014-08-20 | Lb46 Ltd | Cosmetic methods and products |
-
2019
- 2019-11-14 US US17/293,825 patent/US20220008475A1/en active Pending
- 2019-11-14 PL PL19800906.0T patent/PL3880217T3/pl unknown
- 2019-11-14 ES ES19800906T patent/ES2970156T3/es active Active
- 2019-11-14 KR KR1020217017728A patent/KR20210091760A/ko unknown
- 2019-11-14 CN CN201980074865.3A patent/CN113164522B/zh active Active
- 2019-11-14 IL IL282359A patent/IL282359B2/he unknown
- 2019-11-14 AU AU2019380640A patent/AU2019380640A1/en active Pending
- 2019-11-14 JP JP2021525291A patent/JP7416786B2/ja active Active
- 2019-11-14 CA CA3113888A patent/CA3113888A1/en active Pending
- 2019-11-14 WO PCT/EP2019/081257 patent/WO2020099530A1/en unknown
- 2019-11-14 EP EP19800906.0A patent/EP3880217B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3113888A1 (en) | 2020-05-22 |
| EP3880217A1 (en) | 2021-09-22 |
| JP2022509053A (ja) | 2022-01-20 |
| JP7416786B2 (ja) | 2024-01-17 |
| PL3880217T3 (pl) | 2024-05-20 |
| ES2970156T3 (es) | 2024-05-27 |
| US20220008475A1 (en) | 2022-01-13 |
| IL282359B1 (he) | 2023-10-01 |
| AU2019380640A1 (en) | 2021-04-22 |
| KR20210091760A (ko) | 2021-07-22 |
| CN113164522A (zh) | 2021-07-23 |
| IL282359A (he) | 2021-05-31 |
| CN113164522B (zh) | 2024-08-27 |
| EP3880217B1 (en) | 2024-01-03 |
| EP3880217C0 (en) | 2024-01-03 |
| WO2020099530A1 (en) | 2020-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3880217B1 (en) | Methods for preparing platelet releasate | |
| KR101922538B1 (ko) | 상처 치유 조성물의 제조를 위한 방법, 튜브 및 장치 | |
| CA2840568C (en) | Compositions, uses, and preparation of platelet lysates | |
| US7462268B2 (en) | Particle/cell separation device and compositions | |
| JP6649257B2 (ja) | 濃厚血小板から誘導可能な生理活性組成物並びにその調製方法及び使用方法 | |
| JP6995752B2 (ja) | 細胞拡大培養方法及び治療用組成物 | |
| CN108653327B (zh) | 一种用于慢性皮肤损伤治疗的分泌型富血小板凝胶的制备方法 | |
| US20210198626A1 (en) | Compositions and methods for cell culture | |
| AU2023206197A1 (en) | Enhanced multipotent cells and microvascular tissue and methods of use thereof | |
| EP3070164A1 (en) | System and method for providing isolated concentrated multipotent stromal cells for administration | |
| RU2638796C1 (ru) | Способ получения двухкомпонентного препарата для лечения повреждения суставов путем малоинвазивного введения в суставную сумку и препарат, полученный этим способом | |
| CN111172106A (zh) | 一种从人胎盘或脐带中提取间充质干细胞及提取其分泌物的方法 | |
| CN107937334A (zh) | 一种细胞因子提取物及其应用 | |
| Ruiz‐Lopez et al. | Complications in Regenerative Medicine | |
| Yurtbay et al. | Stem cell therapy in knee osteoarthritis, a recent literature review | |
| Coat | PRP is derived from autologous venous blood. Blood is withdrawn from a patient’s vein, and centrifuged, inducing cell and platelet separation in suspension based on their den-sities. Fractionally, red blood cells (RBCs) are the heaviest and layer at the bottom, followed by white blood cells | |
| Goczyńska et al. | Innovative applications of platelet derivatives in light of information presented during the 2022 virtual congress of the International Society of Blood Transfusion (ISBT); selected issues | |
| Qureshi | Use of Autologous Platelet-Rich Plasma Versus Fetal Bovine Serum in Mesenchymal Stem Cells Culture Media | |
| JP2023158599A (ja) | 再生医療用製剤及びその製造方法 | |
| Kevy et al. | Point of care concentration of bone marrow | |
| MX2014001981A (es) | Método de formación de apósito biológico para regeneración de piel (tegumento) y sus anexos tegumentarios mediante células adherentes clonogénicas de origen endometrial. |